DAPTA

DAPTA (D-Ala1-peptide T-amide) is a synthetic peptide derived from the HIV envelope protein gp120. It acts as an entry inhibitor by blocking the binding and infection of viral strains that use the CCR5 receptor to infect cells. Originally developed as a modified analog of Peptide T for clinical trials in HIV/AIDS and neurocognitive disorders associated with HIV (NeuroAIDS), it has also been investigated for potential benefits in conditions such as psoriasis and neurodegenerative diseases. The mechanism involves antagonism of chemokine receptors CCR5 (and possibly CCR2), thereby inhibiting synaptotoxic actions mediated by amyloid beta, alpha-synuclein, and HIV gp120. Early formulations included intranasal administration; later developments led to more stable oral forms such as RAP-103[1][2].

Brand names

Adaptavir

Other names

(D-Ala1)-peptide T amideD-Ala-peptide T-amidePeptide t amide 1(d-ala)L-Threoninamide D-alanyl-L-seryl-L-threonyl-L-threonyl-L-threonyl-L-asparaginyl-L-tyrosyl-CHEMBL181276CHEMBL-181276CHEMBL 181276J208V4ZMP2J-208V4ZMP2J 208V4ZMP2